HomeEXECUTIVESThomas Axelsson, CEO of Vitrolife to Retire

Thomas Axelsson, CEO of Vitrolife to Retire

Thomas Axelsson, CEO of Vitrolife AB, informed the Board of Directors of his desire and intention to retire and be released from his position.

Consequently, the process to find a new CEO to replace Thomas Axelsson will immediately begin and will be led by Jon Sigurdsson, Chairman of the Board. Thomas will remain as the CEO until the recruitment process is finalized.

“Since Thomas joined as the CEO in 2011, he has achieved a remarkable value creation and profitable growth. His outstanding leadership and engagement have been essential for colleagues, partners customers, and shareholders. The Board and I want to thank Thomas for his contribution and aim to make the transition into a new leader for the Vitrolife Group as smooth as possible,” says Jon Sigurdsson.

“Ever since I entered Vitrolife, I have felt a strong passion for the dedicated difference we are making for people when we contribute to fulfilling their dream of having a baby. It has been a good journey together and while I will miss the dynamism of the business and all people involved, I have arrived at the conclusion that it is time for a new phase in life,” says Thomas Axelsson.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

EXECUTIVES ON THE MOVE

Dr John Parker will work closely with PeriGen's client base to optimize use of the company's analytics for patient care and research. He will also be instrumental in informing product development and regulatory affairs as PeriGen continues to expand its product suite and associated services.
“We’re delighted to welcome Gerald and Hannah to the PrecisionLife team at a time when our deep disease insights and patient stratification biomarkers are finding important new markets and bringing precision approaches to the early, more accurate diagnosis and care of patients with complex chronic diseases,” said Dr Steve Gardner, PrecisionLife CEO.
Broken String Biosciences reports Gavin Burns will be responsible for building and optimizing the companys teams, processes, and systems.
“We are pleased to strengthen our Clinical Advisory Board and to welcome our new members,” commented Pierre Leurent, President, Aptar Digital Health. “Their broad medical expertise will allow us to have a deeper knowledge and expand our global vision of the clinical practice for multiple types of cancer.”
Dr Ronald Silverman will be responsible for leading the company's Medical Affairs organization, which includes end-to-end medical affairs across BD's business units, regions and central team. In this role, he will use medical insights and expertise to advance BD's pipeline of clinically relevant, innovative solutions that align with evolving patient needs, while also contributing to the safety and compliance of BD's in-market portfolio of products.

By using this website you agree to accept Medical Device News Magazine Privacy Policy